What is ADC Therapeutics?
ADC Therapeutics SA operates at the intersection of advanced antibody engineering and potent therapeutic payload delivery. The company is dedicated to the discovery, development, and commercialization of targeted oncology medicines. By focusing on antibody drug conjugates, the firm aims to selectively neutralize cancer cells while mitigating systemic toxicity, a significant challenge in traditional chemotherapy. This precision-medicine approach positions ADC Therapeutics as a vital innovator in the treatment of difficult-to-manage malignancies, leveraging a robust R&D engine to translate complex biological insights into viable clinical outcomes.
How much funding has ADC Therapeutics raised?
ADC Therapeutics has raised a total of $1.2B across 10 funding rounds:
Series B
$40M
Unspecified
$80M
Share Placement
$105M
Series D
$105M
Series E
$303M
Stock Offering
$267.6M
Private Equity
$6.3M
Debt
$175M
Stock/Share Issuance
$100M
Series B (2013): $40M led by Auven Therapeutics and MedImmune
Unspecified (2015): $80M supported by AstraZeneca and Auven Therapeutics
Share Placement (2016): $105M featuring Wild Family Office, AstraZeneca, and Auven Therapeutics
Series D (2016): $105M backed by Auven Therapeutics and AstraZeneca
Series E (2019): $303M with participation from Redmile Group, Wild Family Office, AstraZeneca, and Auven Therapeutics
Stock Issuance/Offering (2020): $267.6M, investors not publicly disclosed
Private Equity (2022): $6.3M supported by Owl Rock Capital
Debt (2022): $175M featuring Oaktree and Owl Rock Capital
Stock/Share Issuance (2025): $100M, investors not publicly disclosed
Key Investors in ADC Therapeutics
AstraZeneca
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines. Its portfolio spans oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, infectious diseases and rare diseases.
Redmile Group
Redmile Group LLC is a company that operates in the Venture Capital & Private Equity industry, focusing on high-growth healthcare and life sciences investments.
Oaktree
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments, recognized for its opportunistic and risk-controlled approach to credit and equity markets.
What's next for ADC Therapeutics?
With the recent influx of capital, ADC Therapeutics is well-positioned to advance its late-stage clinical programs and optimize its manufacturing capabilities. The strategic focus will likely shift toward scaling the commercialization of its lead assets while simultaneously exploring next-generation payload technologies. By maintaining a disciplined approach to capital allocation, the company is poised to strengthen its market position, potentially attracting further institutional interest as it moves toward long-term value creation in the biopharmaceutical sector.
See full ADC Therapeutics company page
